Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of...
Background: Esketamine and ketamine have been shown to produce rapid antidepressant action in patients with treatmentresistant depression (TRD). The aim of the current study was to assess the efficacy, safety and dose response of intranasal esketamine in patients with TRD. Methods: This was a 2-Panel, doubly-randomized, double-blind, placebo-controlled, multicenter study. Panel A was conducted...
Specific objective of the study: This study is aimed to investigate desipramine, venlafaxine and bupropion on depression and anxiety in mice. Methods used: We used a classic tricyclic antidepressant, desipramine; a serotonin-norepinephrine reuptake inhibitör, venlafaxine; a second-generation antidepressant agent that blocks centrally the reuptake of noradrenaline and dopamine, bupropion in...
Background: Esketamine and ketamine have been shown to produce rapid antidepressant action in patients with treatmentresistant depression (TRD).The aim of the current study was to assess the efficacy, safety and dose response of intranasal esketamine in patients with TRD.Methods: This was a 2-Panel, doubly-randomized, double-blind, placebo-controlled, multicenter study.Panel A was conducted in...
Among the opioid receptors, the κ-opioid receptor (κOR) has been gaining considerable attention as a potential therapeutic target for the treatment of complex CNS disorders including depression, visceral pain, and cocaine addiction. With an interest in discovering novel ligands targeting κOR, we searched natural products for unusual scaffolds and identified collybolide (Colly), a nonnitrogenous...
This study is an examination of the positive and persisting psychological and behavioral aftereffects in eight individuals who reported consumption of psilocybin-containing mushrooms. Mushrooms containing psilocybin have been used for healing and spiritual purposes for thousands of years, and the therapeutic applications of psilocybin were scientifically examined beginning in the mid-20th...
Not so fast. There’s a long way to go. But a study in London has shown that the active ingredient in magic mushrooms, psilocybin, may be effective against treatment resistant depression. Its effects were quick—within a week—and more than 40% of the patients treated were still in remission three months later.1 Yes, as far as it goes. These were people whose depression had …
Peer victimization increases the risk of experiencing psychotic symptoms among clinical and general populations, but the mechanism underlying this association remains unclear. Dissociation, which is related to peer victimization and hallucinatory experiences, has been demonstrated as a significant mediator in the relation between childhood victimization and hallucinatory experience among adult...
The search for the basis of religious experience among neurological processes in the brain has resulted in a widespread debate within, as well as outside the academic world. The aim of this paper is to analyze to what extent a neuro-psychological theory could explain the phenomenon of religious experience. To clarify what the neuro-psychological studies of the present paper mean by the concept...
Novel cannabinoid compounds continue to be marketed as "legal" marijuana substitutes, even though little is known about their molecular and behavioral effects. Six of these compounds (ADBICA, ADB-PINACA, THJ-2201, RCS-4, JWH-122, JWH-210) were tested for in vitro and in vivo cannabinoid-like effects to determine their abuse liability. Binding to and functional activity at CB1 cannabinoid...